

1 *Anticoagulation-related complications and their outcomes in*
2 *hemodialysis patients with acute kidney injury at selected*
3 *hospitals in Ethiopia.*

4 Hanan Muzeyin Kedir (hanan.muzeyin@aau.edu.et)^{1*}, Abdella Birhan Yabeyu
5 (birhanabdella@gmail.com)², Addisu Melkie Ejigu (addisumelkieejigu@gmail.com)³, Tamrat
6 Assefa Tadesse (tamrat.assefa@aau.edu.et)¹, Eskinder Ayalew Sisay
7 (eskinder.ayalew@aau.edu.et)¹

8 ¹Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health
9 Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

10 ²Department of Pharmacy, College of Medicine and Health Sciences, Ambo University, Ambo,
11 Ethiopia.

12 ³Department of Internal Medicine, Addis Ababa University, Addis Ababa, Ethiopia

13 ***Correspondence Author**

14 Hanan Muzeyin Kedir

15 hanan.muzeyin@aau.edu.et

16 Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Collage of Health
17 Sciences, Addis Ababa University, Addis Ababa, Ethiopia.

18 Telephone: +251912275828

19 These authors contributed equally to this work.

20 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

21 **Abstract**

22 **Introduction:** During hemodialysis (HD), the presence of clots in the dialyzer can diminish
23 the effective surface area of the device. In severe cases, clot formation in the circuit can halt
24 treatment and lead to blood loss in the system. Thus, ensuring proper anticoagulation during
25 HD is crucial to prevent clotting in the circuit while safeguarding the patient from bleeding
26 risks. This study aimed to evaluate anticoagulation outcomes and related factors in HD patients
27 with acute kidney injury (AKI) at selected hospitals in Ethiopia.

28 **Method:** A prospective, multicenter observational study was carried out between October 1,
29 2021, and March 31, 2022. The study encompassed all AKI patients undergoing HD at least
30 once during the study period. Descriptive statistics were utilized to summarize the data, and
31 multinomial logistic regression analysis was employed to identify factors associated to clotting
32 and bleeding.

33 **Results:** Data were gathered from 1010 HD procedures conducted on 175 patients.
34 Extracorporeal circuit clotting was detected in 34 patients during 39 (3.9%) dialysis sessions,
35 while bleeding incidents occurred in 27 patients across 29 (2.9%) sessions. A statistically
36 significant association was found between both the total number of HD treatments and blood
37 flow rate with incidents of clotting. Factors such as length of hospitalization, serum creatinine
38 levels at admission, signs and symptoms associated with uremia, along with utilization of
39 anticoagulants or antiplatelet medications demonstrated an association with bleeding events.

40 **Conclusion:** Clotting affected 19.4% of participants, while bleeding occurred in 15.4%,
41 underscoring the importance of close monitoring. The frequency of HD sessions and blood
42 flow rate are correlated with clotting, while hospitalization duration, serum creatinine levels,
43 uremic symptoms, and anticoagulant use are associated with bleeding events.

44 **Keywords:** Acute kidney injury, Anticoagulation, Hemodialysis, Ethiopia

45

46 **Introduction**

47 Hemodialysis (HD) constitutes a medical procedure that facilitates the removal of waste
48 products from the bloodstream externally via a device outfitted with specialized filtration
49 systems. The predominant cause for arteriovenous access failure is attributed to thrombosis,
50 representing 80%-85% of cases (1,2). Within the HD protocol, components such as the dialyzer
51 and other elements of the extracorporeal blood circuit are also vulnerable to thrombotic events.
52 This includes tubing, arterial and venous bubble traps in addition to needles or catheters utilized
53 for vascular access—all factors contributing to coagulation phenomena (3,4). Notably, arterial
54 and venous bubble traps exhibit a heightened susceptibility towards clotting owing to
55 diminished blood flow rates leading potentially to stasis and hence clot formation. Such
56 premature cessation of HD sessions precipitates inadequate dialysis alongside possible
57 hematologic losses. Furthermore clots within this circuitry can herald significant negative
58 repercussions including reduction in solute clearance during therapy amplified costs, and
59 increased operational burden (5-7).

60 Maintaining an optimal balance between insufficient and excessive heparinization is essential
61 for achieving proper anticoagulation during HD in order to avert bleeding and clot formation
62 within the extracorporeal circuit, respectively (6, 8). It is imperative to administer the minimal
63 efficacious dose of anticoagulant to ensure that the dialyzer and venous chamber remain clear
64 of blood cell fragments while also facilitating rapid hemostasis at the vascular access site
65 following treatment (5). Although anticoagulant dosing varies among individuals due to patient-
66 specific factors and HD-related variables, it is generally lower than doses required for full

67 anticoagulation. Inadequate levels of anticoagulation may reduce dialysis's effectiveness in
68 eliminating waste products from the bloodstream (4-6).

69 Unfractionated heparin (UFH) is extensively utilized as an anticoagulant during HD owing to
70 its long-standing history in clinical practice and a desirable safety profile characterized by a
71 brief half-life (8,9). The European guidelines for optimal HD practices suggest an initial bolus
72 of 50 IU/kg UFH administered via the arterial access needle, followed by a continuous infusion
73 maintenance dosage ranging from 500 to 1500 IU of UFH per hour. It's recommended that the
74 use of UFH be minimized, especially since patients with acute kidney injury AKI often have
75 compromised health and may require daily dialysis treatments. In instances of clotting or
76 bleeding, modifications in dosage or the implementation of heparin-free dialysis methods might
77 become necessary. Although alternative anticoagulation techniques targeting the extracorporeal
78 circuit exist, their adoption has been limited due to their complex nature and higher requisites
79 for administration time and workforce involvement for monitoring purposes (10-12).

80 Critically ill patients often display impaired coagulation and low platelet counts, which
81 significantly increases their risk of bleeding when systemic anticoagulants are used. As such, it
82 is advised that these individuals avoid any treatments that further heighten this risk, especially
83 those involving systemic anticoagulants (6,13). In situations where the risk of bleeding is a
84 concern, the European Best Practice Guidelines recommend alternatives like regular saline
85 flushing or local citrate anticoagulation during HD, avoiding systemic anticoagulants entirely.
86 This approach not only facilitates quick adjustments to treatment but also enables easy
87 monitoring for clotting within the dialyzer and may help in preventing clots from forming
88 initially (2,10). The goal of this study is to explore outcomes related to anticoagulation therapy
89 and factors influencing its outcome among AKI patients receiving HD at Tikur Anbessa

90 Specialized Hospital (TASH) and St. Paul's Hospital Millennium Medical College (SPHMMC)
91 in Addis Ababa, Ethiopia.

92 **Material and Methods**

93 **Study Setting**

94 The study took place in the dialysis departments of TASH and SPHMMC, located in Addis
95 Ababa, Ethiopia. TASH introduced HD services back in 1980 and presently caters to acute
96 dialysis needs. Meanwhile, SPHMMC began its provision of acute dialysis services in August
97 2013 before extending these services to include maintenance dialysis for kidney transplantation
98 starting from early 2015 (14).

99 Despite the lack of a specific written protocol for HD patients, anticoagulation was frequently
100 administered at both hospitals. UFH was used during HD, but the prescribed doses of heparin
101 varied slightly between the two centers. At TASH, UFH was administered in one of three ways:
102 (i) the standard dose, 1 ml (5000 IU) of UFH, was diluted with 4 ml of normal saline (total of
103 5 ml). This was followed by a 2 ml initial bolus and a continuous infusion of 1 ml/hr; (ii) the
104 minimal or half dose of 0.5 ml (2500 IU) of UFH was diluted with 4.5 ml of normal saline
105 (total of 5 ml). This was followed by a 2 ml initial bolus and a continuous infusion of 1 ml/hr;
106 (iii) heparin-free saline flushes of 30 to 50 ml were given every 30 minutes. At SPHMMC, 1
107 ml of UFH was diluted with 3 ml of normal saline (total of 4 ml) and administered as a bolus
108 of 1 ml, followed by a continuous infusion of 1 ml/hr.

109 **Study Design and Period**

110 A comprehensive, multicenter observational study was carried out over a duration of six months,
111 starting from **October 1st, 2021 and concluding on March 31st, 2022**. This study took place at
112 two major hospitals (TASH and SPHMMC) in Addis Ababa, Ethiopia.

113 **Sampling and Sample Size Determination**

114 On average, the dialysis clinics at TASH and SPHMMC serve approximately 15 and 30 AKI
115 patients per month, respectively. All patients meeting the eligibility criteria were considered
116 for inclusion in the study. Consequently, a total of 175 patients identified during the study
117 period, meeting the established criteria, participated in this research. Specifically, 122 of these
118 patients received treatment at SPHMMC, while the remaining 53 were from TASH.

119 **Inclusion and Exclusion Criteria**

120 All patients suffering from AKI, aged 12 years and older, who underwent HD at least once
121 during the designated study period were eligible for inclusion in this study. Nonetheless,
122 individuals diagnosed with chronic kidney disease who were undergoing regular maintenance
123 dialysis treatments, as well as those who expressed a refusal to participate in the study, were
124 systematically excluded from consideration.

125 **Data Collection Instruments and Techniques**

126 The data collection questionnaire, consisting of four sections, was developed through a
127 thorough review of relevant literature related to the study's objectives. The aim was to collect
128 demographic characteristics and clinical variables of patients to assess outcomes related to

129 anticoagulation. Pre-testing was carried out, and all necessary adjustments to the data collection
130 tool were implemented(4,6,9,15–18).

131 The initial section of the data collection tool was designed to gather information regarding the
132 sociodemographic characteristics of the patients. Subsequently, the second section assessed the
133 clinical features of the patients, including inquiries about the cause of AKI, indications for HD,
134 concomitant medical conditions, co-administered medications, and current use of
135 anticoagulants and/or antiplatelet drugs. The third part of the data collection tool focused on
136 recording essential laboratory results upon admission and discharge. Finally, the fourth section
137 specifically documents the comprehensive details of each HD session. Patients were closely
138 monitored during each session, with data collectors prospectively recording various parameters
139 related to HD, such as venous pressure, ultrafiltration volume, blood flow, dialysate flow, and
140 approach to UFH usage during HD. Additionally, incidents of clotting or bleeding were
141 documented, along with the interventions implemented to manage these occurrences.

142 **Data Quality Assurance**

143 To ensure data quality, the principal investigator closely monitored each activity to ensure
144 comprehensive data collection. Unclear terms were promptly clarified, and the necessary
145 corrections were made during the pre-test phase before commencing the main study. Data
146 collection was performed using three BSc. nurses and a pharmacist who were recruited as data
147 collectors. They underwent training to establish a consistent understanding and interpretation
148 of the instrument, including a briefing on the study's objectives and commitment to maintaining
149 core ethical principles throughout the data collection period.

150 **Data Analysis**

151 Data completeness was verified before entering the statistical package for social science
152 (SPSS) version 26 for a thorough analysis. Descriptive statistics, including the mean, median,
153 percentage, and standard deviation (SD), were then used to succinctly summarize the data.
154 Multinomial logistic regression was used to identify predictive factors for anticoagulation-
155 related outcomes in patients with AKI undergoing HD. A P-value < 0.05 was considered the
156 threshold for declaring statistically significant associations.

157 **Ethical Considerations**

158 Ethical clearance was secured from Addis Ababa University, School of Pharmacy, the Ethical
159 Review Committee (reference number ERB/SOP/257/13/2021), and the Institutional Review
160 Board of SPHMMC (reference number PM25/386). **Study participants provided both written
161 and verbal consent before participating**, and their confidentiality was maintained by avoiding
162 the recording of identifying information such as patient names. The collected data remained
163 securely stored throughout the study and was appropriately destroyed upon study completion.

164 **Operational Definition**

165 Anticoagulation-related complication: were defined as the occurrence of any circuit clotting or
166 bleeding during HD, whether with the use of UFH as an anticoagulant for dialysis or in a
167 heparin-free approach.

168 Results

169 Socio-demographic Characteristics of Study Participants

170 Of the 175 patients included in the study, an almost equal number were males (50.9%) and
171 females (49.1%), with a mean age of 40 ± 17.8 years involved and four female were pregnant.

172 Among the 175 patients, 66.9% were paid out-of-pocket for dialysis and 2.3% were involved
173 in smoking, drinking alcohol, and chewing khat (Table 1).

174 **Table 1: Socio-demographic characteristics of AKI patients who undergo HD (n=175)**

Variable	Category	n (%)
Age (years),mean \pm SD		40 \pm 17.8
Sex	Male	89 (50.9)
	Female	86 (49.1)
Marital status	Single	55 (31.4)
	Married	103 (58.9)
	Widowed	10 (5.7)
	Divorced	7 (4)
Pregnancy	Pregnant	4 (4.7)
	Not pregnant	71 (82.5)
	Postpartum	11 (12.8)
Education	Unable to read and write	23 (13.1)
	Primary education	42 (24)
	Secondary education	63 (36)

	Diploma and above	47 (26.9)
Weight (Kg)		61±13.9
Method of payment	Insurance	58 (33.1)
	Out of pocket	117 (66.9)
Substance use	Smoking	7 (4)
	Chewing Khat	9 (5.1)
	Alcohol	26 (14.9)
	Smoking + Khat + Alcohol	4 (2.3)

175

176 **Clinical Characteristics**

177 The average length of hospital stay was 14.2 days, range, 2–40 days. The three most common
 178 causes of AKI were acute tubular necrosis (29%), nephrotic syndrome (24%), and sepsis
 179 (22.9%). Pregnancy-related causes also included preeclampsia/eclampsia (5.1%) and HELLP
 180 syndrome (4.6%). The major indications for dialysis were uremic signs and symptoms (70.3%),
 181 followed by fluid overload (50.3%). Common underlying comorbidities identified were
 182 hypertension (55.4%) and anaemia (49.7%), and 13.1% of AKI cases were superimposed on
 183 chronic kidney disease. UFH 7500 IU twice per day (48%) was the most widely used
 184 anticoagulant regimen in the study population, followed by 5000 IU twice a day (14.3%) to
 185 prevent deep venous thrombosis (Table 2).

186 **Table 2: Clinical characteristics of AKI patients who undergo HD (n=175)**

Variables	Category	n (%)
		Yes

Length of hospitalization (days), mean \pm		14.2 \pm 9.9
SD		
Cause of AKI	Acute tubular necrosis	49 (28)
	Nephritic syndrome	42 (24)
	Sepsis	40 (22.9)
	Severe dehydration	17 (9.7)
	Interstitial nephritis	25 (14.3)
	Shock	19 (10.9)
	Poison	17 (9.7)
	Urinary tract obstruction	11 (6.3)
	Nephrotoxic drugs	8 (4.6)
	Rhabdomyolysis	3 (1.7)
	HELLP syndrome	8 (4.6)
	Post-kidney transplant rejection	6 (3.4)
	Lupus nephritis	9 (5.1)
	Preeclampsia/Eclampsia	9 (5.1)
	Acute Glomerulonephritis	7 (4)
	Hemorrhage	5 (2.9)
	Others*	4 (2.3)
Dialysis indication	Uremic signs and symptoms	123 (70.3)
	Fluid overload	88 (50.3)
	Hyperkalemia	79 (45.1)
	Metabolic Acidosis	66 (37.7)

Comorbidity	Atrial fibrillation	1 (0.6)
	Coronary arterial disease	1 (0.6)
	Stroke	6 (3.4)
	Hypertension	97 (55.4)
	Congestive heart disease	22 (12.6)
	Gastrointestinal ulceration	29 (16.6)
	Chronic Kidney Disease	23 (13.1)
	Anemia	87 (49.7)
	Deep vein thrombosis	5 (2.9)
	Pulmonary embolism	3 (1.7)
	Type 2 Diabetes	22 (12.6)
	HIV	11 (6.3)
	Pulmonary tuberculosis	9 (5.1)
	Hepatitis B virus	5 (2.9)
	Others**	41 (23.4)
Concurrent anticoagulant and/or antiplatelet	124 (70.9)	
	UFH 2500 IU SC BID	1 (0.6)
	UFH 5000IU SC Bid	25 (14.3)
	UFH 7500IU SC Bid	84 (48)
	UFH 17500IU SC Bid	5 (2.9)
	Warfarin 5mg PO Daily	8 (4.6)
	ASA 81mg PO Daily	20 (11.4)
	Enoxaparin 40mg SC Bid	3 (1.7)
	Clopidogrel 75mg PO Daily	2 (1.1)

Concomitant drugs use 166 (94.9)

187 * (*malaria, kidney trauma, cardio-renal syndrome, acute fatty liver of pregnancy*)

188 ** (*prostate cancer, BPH, epilepsy, leukemia, gout arthritis, cerebral malaria*)

189 Laboratory Findings

190 Upon admission and upon discharge, it was noted that there were low hemoglobin levels present.
 191 Furthermore, the mean serum creatinine level recorded at the time of admission stood at $8.3 \pm$
 192 3.4 mg/dl, which experienced a significant decrease by 3 mg/dl by the time of discharge. Table
 193 3 in our document provides a summarized outline showing these changes among other selected
 194 laboratory parameter values observed during this period.

195 **Table 3: Selected Laboratory Values of AKI patients who undergo HD (n=175)**

Variables	Mean \pm SD	
	Admission	Discharge
Hemoglobin (g/dl)	10.3 ± 7.6	10.3 ± 6.4
WBC count (10^3 /ml)	11.1 ± 5.6	9.8 ± 4.9
Platelet count (10^3 /ml)	235.9 ± 140.1	268.3 ± 131
Serum creatinine (mg/dl)	8.3 ± 3.4	5.3 ± 3.1
Urea (mg/dl)	137.5 ± 80.3	82.1 ± 63.4
Serum potassium (mEq/L)	5.3 ± 1.1	4.4 ± 0.8

196

197 **Characteristics of HD Sessions**

198 From October 2021 to March 2022, a total of 1010 HD sessions were conducted on 175 patients.
199 The average frequency of dialysis sessions was calculated at 5.8 ± 3.8 per patient, ranging from
200 one single session to a maximum of fifteen sessions with each session lasting an average
201 duration of approximately 3.1 ± 0.6 hours. Patients underwent HD therapy thrice weekly using
202 catheters as the primary means for vascular access across all cases in this study. During these
203 treatments, blood products were administered in approximately 9.8% or essentially, during
204 almost ten out all hundred HD procedures. UFH was administered for circuit anticoagulation
205 in 626 sessions, accounting for 62% of the total. The average dose given was 1 mL (5000 IU).
206 Of these UFH sessions, infusion was stopped 60 minutes before discontinuation in 546 cases,
207 making up 87.2% of the total. The average pressure in the venous chamber was recorded as
208 125 ± 39.3 mmHg, with the dialysis blood flow rate averaging 227.2 ± 22.8 ml/min.

209 **Table 4: Characteristics of HD sessions included in the study (N=1010)**

Variables	mean \pm SD
Total number of HD sessions (N=1010)	5.8 ± 3.8
HD duration (in hour)	3.1 ± 0.6
Venous chamber pressure (mmHg)	125 ± 39.3
Ultrafiltration volume (ml)	885 ± 650.9
Blood flow rate (ml/min)	227.2 ± 22.8
Dialysate flow rate (ml/min)	481 ± 46.6
Total UFH dose (ml)*	1 ± 0.2
	Category
UFH infusion stopped	n (%)

Before 30 minutes	70 (11.3)
Before 60 minutes	546 (87.2)
Before 120 minutes	8 (1.3)
At the end of dialysis	1 (0.2)

210

211 **Anticoagulation-related complication and HD Outcome**

212 Of the 175 patients, extracorporeal circuit clotting occurred in 34 patients in 39 (3.9%) sessions
 213 and 27 patients in 29 (2.9%) experienced bleeding. HD circuit clotting resulted in the
 214 discarding of the bloodline and early termination of dialysis in 17 sessions. Additionally,
 215 nursing interventions, that is, the use of UFH and a normal saline flush, were required in 10
 216 and 5 sessions, respectively, to prevent abrupt HD treatment interruptions due to circuit
 217 clotting. Some of the measures taken when bleeding occurred included holding UFH at the
 218 time, and for the next session/s (n = 14 sessions), blood transfusion (n = 2 sessions), and
 219 applying pressure at catheter insertion site in 6 sessions (Table 5). On the other hand, the
 220 majority of AKI patients (44.6%) were discharged with improvement, while more than one-
 221 fourth (26.9%) of them died after undergoing HD (Figure 1).

222 **Table 5: Anticoagulation related complication and HD outcome among AKI patients in**
 223 **the study.**

Variables	mean ± SD
Circuit clotting (34 patients, 19.4%)	39 (3.9)
Measures taken when circuit clotting occurs	Discard the blood line and HD terminated early 17 (1.7)

Blood transfusion during HD	99 (9.8)
Using UFH during HD	626 (62)
Additional UFH given	10 (1)
Continued HD by using normal saline flush	5 (0.5)
Return the blood and HD terminated early	2 (0.2)
Manipulate the access and continued HD	3 (0.3)
Use UFH intermittently for the next sessions	2 (0.2)
Bleeding (27 patients, 15.4%)	29 (2.9)
Bleeding from nose	15 (1.5)
Catheter site bleeding	6 (0.6)
Vaginal bleeding	4 (0.4)
Others**	4 (0.4)
Measures taken when bleeding occurs	
Hold UFH at the time, and for the next session/s	14 (1.4)
Blood transfused	2 (0.2)
Applied pressure at catheter insertion site	6 (0.6)
Use UFH intermittently for the next sessions	2 (0.2)
Return the blood and HD terminated early	1 (0.1)

No measure taken 4 (0.4)

224 *1ml=5000 IU

225 ** bleeding form rectum, bloody vomiting, subcutaneous hematoma, bleeding form bullet

226 penetrating injury site

227 **Factors associated with anticoagulation related outcomes**

228 To determine the predictors of anticoagulation-related outcomes during HD (clotting and
229 bleeding risks), multinomial regression analysis was used. Based on the model comparing
230 participants who had HD circuit clotting with those who did not have any clotting/bleeding,
231 as the total number of HD sessions increased, the probability of circuit clotting increased
232 (AOR=1.932, 95% CI, 1.227-3.043, p= 0.004). In contrast, a higher blood flow rate was
233 associated with a lower HD circuit clotting risk (AOR=0.868, 95% CI, 0.812-0.928, p=
234 0.001).

235 On the other hand, bleeding was more likely to occur in participants who had longer
236 hospitalization and elevated serum creatinine at admission (AOR=1.247, 95% CI, 1.053-1.478,
237 p= 0.010; AOR=1.886, 95% CI, 1.285-2.769, p= 0.001) respectively. While, the rate of
238 bleeding in patients who had no uremic signs and symptoms was lower (AOR=0.092, 95% CI,
239 0.009-0.955, p= 0.004) than those having it. Likewise, patients who did not receive
240 prophylactic or therapeutic anticoagulant and/or antiplatelet drug were less likely to develop
241 bleeding (AOR=0.017, 95% CI, 0.001-0.446, p= 0.014) compared to those taking these drugs
242 (Table 6).

243 **Table 5: Multinomial regression of predictive factors associated with anticoagulation**
 244 **related outcomes during HD**

Variables	Outcomes		
	Clotting	Bleeding	P-value
	AOR (95% CI)	AOR (95% CI)	
Total no of HD sessions	1.932 (1.227-3.043) ^a	1.068 (0.713-1.601)	0.004*
Blood flow rate (ml/min)	0.868 (0.812-0.928) ^a	1.026 (0.974-1.081)	<0.001*
Length of hospitalization (days)	0.946 (0.843-1.06)	1.247 (1.053-1.478) ^a	0.010*
Serum creatinine (mg/dl) at admission	0.911 (0.699-1.189)	1.886 (1.285-2.769) ^a	0.001*
Uremic signs and symptoms			
Yes	1	1	
No	0.532 (0.079-3.57)	0.092 (0.009-0.955) ^a	0.04*
Using of anticoagulant and/or antiplatelet drug			
Yes	1	1	
No	1.156 (0.168-7.936)	0.017 (0.001-0.446) ^a	0.014*

245 *Reference Variable: No clotting/bleeding*

246 **Variables that showed a significant association, P < 0.05*

247 *^aVariable category with P < 0.05*

248 **Discussion**

249 As the first prospective study in the Ethiopian context on anticoagulation among patients with
250 AKI on HD, this study provides insight into extracorporeal circuit clotting or bleeding
251 occurrences and the predictive factors associated with these complications. In this study, 1010
252 HD sessions performed on 175 patients were prospectively followed. Clotting and bleeding
253 data are expressed as percentages of both participants and sessions. Circuit clotting occurred
254 in 3.9% of HD sessions (19.4% patients), and bleeding in 2.9% sessions (15.4% patients).

255 A similar result was reported in the United States of America, that evaluated clotting of the HD
256 circuit in general care patients and critically ill patients. The overall rate of extracorporeal
257 circuit clotting was 5.2% in all sessions (12). Circuit clotting occurred in 2.4% of HD sessions
258 with heparin, according to a retrospective study comparing two intra-dialytic heparin protocols:
259 "routine heparin-use" during HD (routine heparin prime/bolus dose) and heparin-free HD
260 (saline prime, heparin avoidance). However, heparin-free HD is associated with a higher rate
261 of HD circuit clotting (9.1%) (13). In contrast, other studies reported a higher rate of circuit
262 clotting during HD. A study conducted in Brazil showed that filter clotting occurred in 19
263 patients (25.3%) and 29 sessions (14.9%) (19). This study evaluated and compared intra- and
264 post-dialysis complications in critically ill AKI patients undergoing extended daily dialysis
265 sessions of different durations (6 versus 10 hours), which could explain the higher rate of HD
266 filter clotting events, and the fact that many critically ill patients develop hemostatic
267 abnormalities in addition to the longer dialysis duration.

268 Additionally, a retrospective cohort study conducted in Belgium found that circuit coagulation
269 was reported in 17.5% of the sessions. This higher rate of clotting events could be attributed to
270 the absence of systemic anticoagulation (20). Moreover, this study conducted a retrospective

271 analysis of HD sessions in intensive care unit patients, which could be an additional factor
272 contributing to clotting occurrences. Patients admitted to the intensive care unit and requiring
273 dialysis for AKI often present with a systemic inflammatory state (21), which is known to be
274 associated with the activation of coagulation pathways (22).

275 Lower clotting of the HD circuit incidence was reported in a retrospective study conducted in
276 the USA (1% of 400 HD treatments) (23). This may be attributed to the operational definition
277 of clotting used in this study. The researchers defined clotting as complete clotting that required
278 replacement of the blood tubing and dialyzer to complete treatment. The higher blood flow rate
279 (378 ± 46 mL/min) and more aggressive normal saline flushing of the circuit employed in this
280 protocol could also explain the lower rate of clotting. Moreover, there might be underreporting
281 of clots due to the retrospective study design, in which existing data were extracted from chart
282 reviews. Another study from Spain found that 1.9% of patients developed clotting, which is
283 lower than our finding (19.4% of patients) with a higher mean blood pump flow (346 ± 47
284 ml/min), given a higher risk of coagulation from a lower pump flow (17).

285 In the current study, 15.4 % of patients developed bleeding, and this finding was higher than a
286 study conducted in Spain (4.4%) (17). This variation might be due to the difference in the study
287 design and setting, even though the study reported that oral anticoagulants were administered
288 to 18.4% of patients, which by itself is thought to increase the risk of bleeding. However, in a
289 Spanish study, each patient was asked to report any bleeding or thrombotic complications that
290 arose in the week prior to data collection.

291 In the present study, it was observed that anticoagulation was achieved with UFH or saline
292 flushes of 30 to 50 ml administered every 30 min if UFH was contraindicated. There were three
293 strategies regarding UFH order for HD in current study settings, and each patient was dialyzed
294 using any of these anticoagulation methods. The first is the standard dosing regimen of UFH,

295 consisting of a bolus of 1250–2000 U, followed by a continuous infusion of 1000–1250 U/h.
296 The second was the minimal/half-dose method with a 625–1000 bolus dose and 500–625
297 infusion rate. Heparin-free dialysis was also the third method used in patients who were
298 actively bleeding or were at an increased risk of bleeding.

299 Due to its brief half-life and extensive medical usage over time, UFH has emerged as the
300 predominant anticoagulant for HD (9). Nonetheless, the dosage administered shows significant
301 divergence. This study reveals that the average total UFH dose throughout HD sessions was
302 5000 ± 1000 units, with heparin infusion being discontinued one hour before dialysis
303 completion in the majority (87.2%) of cases to reduce the potential for bleeding from the access
304 site post needle withdrawal.

305 In the present study, extracorporeal circuit clotting was assessed by visual inspection and noted
306 by nurses. It is characterized by extremely dark blood or black striations in the tube and a
307 sudden rise in pressure readings. They only recorded clotting as being present or absent without
308 grading it in line with several studies done elsewhere (13,17,19,24). In contrast, other studies
309 have reported the degree of clotting by classifying it as mild/slight, moderate, and severe.

310 HD is often performed three times a week for three–four hours each session; however, the
311 length of these sessions varies from patient to patient. One consequence of intradialysis, circuit
312 clotting, includes treatment interruption and patient blood loss, which may exacerbate
313 haemodynamic instability (19). In 1.7% of all sessions with clotting, dialysis was stopped early
314 without the possibility of retransfusing blood from the extracorporeal circuit; hence, the
315 bloodline was discarded. However, in 0.2% of the sessions, dialysis was terminated early by
316 the return of blood.

317 According to a study from Belgium, clotting reduced the length of time spent receiving dialysis
318 in 15.2% of sessions, completely blocking the circuit, and preventing retransfusion in 4.2% of
319 sessions, which is greater than our findings (20). These variations may be due to differences in
320 dialysis protocols. In contrast to our study, the study combined a citrate-enriched dialysate with
321 a heparin-coated dialyzer with no systemic UFH. Similarly, a study conducted in the USA
322 comparing two intradialytic heparin protocols reported that in a heparin-free HD protocol,
323 circuit clotting resulted in a change of the extracorporeal circuit in 7.3% of sessions. However,
324 this was required in only 0.8% of HD sessions with heparin, and early termination of HD
325 (1.6%) was similar to that in this study (13). Bleeding is another important intradialysis
326 complication that might require adjusting the dose of UFH (1.6% of all sessions with bleeding)
327 or blood transfusion (0.2%). Another study revealed that patient weight, circuit clotting, and
328 bleeding of the vascular access after disconnection were the most frequently employed
329 techniques for changing the dosage (17).

330 Identifying predictors of anticoagulation-related outcomes during HD in patients with AKI is
331 important. Identifying and preventing patients at risk of such complications can increase
332 practitioner awareness of HD-related complications. Similar to other studies (12,13,20,23), the
333 blood flow rate showed a statistically significant association with the occurrence of circuit
334 clotting. In this study, lower delivered blood flow rates were associated with higher circuit-
335 clotting rates. Additionally, as the total number of HD sessions increased, the probability of
336 circuit clotting increased, unlike in a study conducted in Belgium (20). This difference could
337 be due to variations in their research methodology and the inclusion of study participants with
338 varying levels of clotting risk. Patients who did not receive prophylactic or therapeutic
339 anticoagulants and/or antiplatelet drugs were less likely to develop bleeding compared to those
340 taking these drugs. Similarly, a study from Spain found that bleeding complications were more

341 frequent in patients receiving oral anticoagulants (17). Consistent with previous studies, age
342 and sex were not associated with bleeding events (13,17).

343 However, there were some limitations to our study. Bleeding was reported only at the time of
344 the dialysis session. Therefore, this may not provide a comprehensive picture of the bleeding
345 risk associated with dialysis. Additionally, the study did not exclude patients with
346 comorbidities (such as deep vein thrombosis, active malignancy, severe heart failure, or severe
347 liver disease). These conditions can impact anticoagulation outcomes and may confound the
348 interpretation of results.

349 **Conclusions**

350 In conclusion, clotting was observed in 19.4% of the participants in the study, while bleeding
351 was reported in 15.4% of them. These findings highlight the importance of thorough
352 monitoring due to the complications resulting in treatment interruptions and blood loss. The
353 study identified a significant association between circuit clotting and variables such as blood
354 flow rate and the frequency of HD sessions. Furthermore, it revealed a notable occurrence of
355 bleeding during HD, mainly manifesting as minor cases. Individuals who received prophylactic
356 or therapeutic anticoagulants and/or antiplatelet medications were more susceptible to bleeding
357 compared to those who did not undergo these treatments.

358

359 **Abbreviations**

360 AKI: Acute Kidney Injury; HD: Hemodialysis; SPHMMC: St. Paul's Hospital Millennium
361 Medical College; TASH: Tikur Anbessa Specialized Hospital; UFH: Unfractionated heparin.

362 **Acknowledgement**

363 The authors thank the School of Pharmacy, College of Health Sciences, Addis Ababa
364 University, and the nursing staff at TASH and SPHMMC dialysis clinics, who were very
365 cooperative and helpful in providing constant assistance.

366 **Availability of Data and Materials**

367 All the data and materials used in this paper are available from the corresponding author upon
368 reasonable request.

369 **Disclosure interest**

370 The authors declare that they have no conflicts of interest.

371 **Funding details**

372 The authors received no specific funding for this study.

373

374

375

376

377

378

379

380

381

382


383

384 **References**

- 385 1. Chawla LS, Amdur RL, Amodeo S, Kimmel PL, Palant CE. The severity of acute
386 kidney injury predicts progression to chronic kidney disease. *Kidney Int.*
387 2011;79(12):1361–9.
- 388 2. Daugirdas JT, Blake PG, Ing TS. Handbook of dialysis: Fifth edition. Handbook of
389 Dialysis: Fifth Edition. 2014. 1–900 p.
- 390 3. Dirkes S, Wonnacott R. Continuous Renal Replacement Therapy and Anticoagulation:
391 What Are the Options? *Am Assoc Crit Nurses.* 2016;36(2):1–12.
- 392 4. Ross S. Anticoagulation in Intermittent Hemodialysis: Pathways, Protocols, and
393 Pitfalls. *Vet Clin North Am - Small Anim Pract.* 2011;41(1):163–75.
- 394 5. Fischer KG. Essentials of anticoagulation in hemodialysis. *Hemodial Int.*
395 2007;11(2):178–89.
- 396 6. Mhatre V, Ho, Ji-Ann Lee and KCM. Use and Safety of Unfractionated Heparin for
397 Anticoagulation During Maintenance Hemodialysis. *Am J Kidney Dis.* 2012;23(1):1–
398 7.
- 399 7. Srisawat N, Lawsin L, Uchino S, Bellomo R, Kellum JA. Cost of acute renal
400 replacement therapy in the intensive care unit: Results from The Beginning and Ending
401 Supportive Therapy for the Kidney (BEST Kidney) Study. *Crit Care.* 2010;14(2):1–10.
- 402 8. Kessler M, Moureau F, Nguyen P. Anticoagulation in Chronic Hemodialysis: Progress
403 Toward an Optimal Approach. *Semin Dial.* 2015;28(5):474–89.
- 404 9. Cronin RE, Reilly RF. Unfractionated Heparin for Hemodialysis: Still the Best Option.
405 *Semin Dial.* 2010;23(5):510–5.
- 406 10. European Best Practice Guidelines Expert Group on Hemodialysis ERA. Section V.
407 Chronic intermittent haemodialysis and prevention of clotting in the extracorporeal
408 system. *Nephrol Dial Transpl.* 2002;17:63–71.
- 409 11. Royal Liverpool and Broadgreen University Hospitals NHS Trust. Protocol for
410 anticoagulation of extracorporeal circuits during kidney replacement therapy or plasma
411 exchange. 2015.
- 412 12. Safadi S, Albright RC, Dillon JJ, Williams AW, Alahdab F, Brown JK, et al.
413 Prospective Study of Routine Heparin Avoidance Hemodialysis in a Tertiary Acute
414 Care Inpatient Practice. *Kidney Int Reports [Internet].* 2017;2(4):695–704. Available
415 from: <http://dx.doi.org/10.1016/j.ekir.2017.03.003>
- 416 13. Liang E. Outcomes Associated with a Heparin-Free Hemodialysis Protocol and
417 Review of the Literature. *J Clin Nephrol Ren Care.* 2016;2(1):1–6.
- 418 14. Muleta MB, Abebe E, Tadesse M, Berhae T, Muhammed M, Woodside K, et al.
419 Original Article Milestones of Renal Replacement Therapy in Ethiopia. *Ethiop Med J.*
420 2020;Supplement(January):5–13.
- 421 15. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Anticoagulant and antiplatelet usage

- 422 associates with mortality among hemodialysis patients. *J Am Soc Nephrol.*
423 2009;20(4):872–81.
- 424 16. Krummel T, Scheidt E, Borni-duval C, Bazin D, Lefebvre F, Nguyen P, et al.
425 Haemodialysis in patients treated with oral anticoagulant : should we heparinize ?
426 2014;29(4):906–13.
- 427 17. Herrero-Calvo JA, González-Parra E, Pérez-García R, Tornero-Molina F. Spanish
428 study of anticoagulation in haemodialysis. *Rev Nefrol.* 2012;32(2):153–9.
- 429 18. Shibiru T, Gudina EK, Habte B, Deribew A, Agonafer T. Survival patterns of patients
430 on maintenance hemodialysis for end stage renal disease in Ethiopia : summary of 91
431 cases. *BMC Nephrol.* 2013;14(1–6).
- 432 19. Albino BB, Balbi AL, Ponce D. Dialysis complications in AKI patients treated with
433 extended daily dialysis: Is the duration of therapy important? *Biomed Res Int.*
434 2014;2014.
- 435 20. François K, Wissing KM, Jacobs R, Boone D, Jacobs K, Tielemans C. Avoidance of
436 systemic anticoagulation during intermittent haemodialysis with heparin-grafted
437 polyacrylonitrile membrane and citrate-enriched dialysate: A retrospective cohort
438 study. *BMC Nephrol.* 2014;15(1):1–7.
- 439 21. Aleksandrova I V., Reš SI, Pervakova EI. Acute renal failure in critically ill patients.
440 *Anesteziol Reanimatol.* 2007;294(4):72–6.
- 441 22. Franchini M, Veneri D, Lippi G. Inflammation and hemostasis: A bidirectional
442 interaction. *Clin Lab.* 2007;53(1–2):63–7.
- 443 23. Sahota S, Rodby R. Inpatient hemodialysis without anticoagulation in adults. *Clin*
444 *Kidney J.* 2014;7(6):1–5.
- 445 24. Murea M, Russell GB, Daeihagh P, Saran AM, Pandya K, Cabrera M, et al. Efficacy
446 and safety of low-dose heparin in hemodialysis. *Hemodial Int.* 2018;22(1):74–81.
- 447

Figure 1: HD outcome among AKI patients in the study



medRxiv preprint doi: <https://doi.org/10.1101/2024.02.28.24303493>; this version posted February 29, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).